Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population

Blood Pressure

Volumn 20, Issue 3, 2011, Pages 166-170

  Ma, Yu ^a   Ni, Wen ^a   Zhu, Wenzhong ^a   Xiong, Yuanchang ^a   Deng, Xiaoming ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytochrome P450; epoxyeicosatrienoic acids; hypertension

Indexed keywords

CYTOCHROME P450 2C19; GLUCOSE;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; FAMILY HISTORY; GENE FREQUENCY; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHINA; DNA FINGERPRINTING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 79957519285     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.542640     Document Type: Article

References (29)

1. Lundell K, Wikvall K.Species-specifi c and age-dependent bile acid composition: Aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis. Curr Drug Metab. 2008;9: 323-331 (Pubitemid 351836421)
2. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, Engstr ö m G, Berglund G, Minuz P, Melander O. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension. 2008;52: 373-380
3. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, Liao JK. Activation of G alphas mediates induction of tissuetype plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001, 276: 15983-15989
4. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004; 109: 178-183 (Pubitemid 38114136)
5. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase J Lipid Res. 2000;41: 163-181 (Pubitemid 30117856)
6. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol. 2000;27: 855-865
7. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;12: 12
8. Ercan B, Ayaz L, Ciç ek D, Tamer L.Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008;26: 309-313 (Pubitemid 351613170)
9. Imig JD. Epoxygenase metabolites. Epithelial and vascular actions. Mol Biotechnol. 2000;16: 233-251 (Pubitemid 32217202)
10. Kinga LM, Gainerb JV, Davida GL, Daia D, Goldsteina JA, Brownb NJ. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenetics Genomics. 2005;15: 7-13
11. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol. 1991;31: 339-369 (Pubitemid 21903852)
12. Fleming I, Busse R. Vascular cytochrome P450 in the regulation of renal function and vascular tone: EDHF, superoxide anions and blood pressure. Nephrol Dial Transplant. 2001;16: 1309-1311 (Pubitemid 32640577)
13. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82: 131-185 (Pubitemid 34654217)
14. Medhora M, Narayanan J, Harder D, Maier KG. Identifying endothelium derived hyperpolarizing factor: Recent approaches to assay the role of epoxyeicosatrienoic acids. Jpn J Pharmacol. 2004;12: 369-375
15. Gauthier KM, Falck JR, Reddy LM, Campbell WB. 14,15- EET analogs: Characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res. 2004;49: 515-524 (Pubitemid 38338661)
16. Sun J, Sui X, Bradbury JA, et al. Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. Circ Res. 2002;90: 1020-1027 (Pubitemid 34633869)
17. Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF. Cytochrome P-450 arachidonate metabolites in rat kidney: Characterization and hemodynamic responses. Am J Physiol. 1990;258: F781-F789 (Pubitemid 20155487)
18. Katoh T, Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, et al. Glomerular stereospecifi c synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol. 1991;261: F578-F586
19. Y ang YN, Wang XL, Ma YT, Xie X, Fu ZY, Li XM, et al. Association of interaction between smoking and CYP 2C19 * 3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thro-/Hem, 2010, DOI: 101177/ 1076029610364522
20. Ercan B, Ayaz L, Ci ç ek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008;26: 309-313 (Pubitemid 351613170)
21. Kitsios GD, Zintzaras E. An NOS3 Haplotype is protective against hypertension in a Caucasian Population. Int J Hypertens. 2010;2010: 865031
22. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from in complete data via the EM algorithm. J R Stat Soc. 1977;39: 1-22
23. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15: 97-98 (Pubitemid 41653949)
24. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;6: 653-658 (Pubitemid 34851922)
25. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am CollCardiol. 2004;10: 1731-1737 (Pubitemid 38622506)
26. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001;39: 36059-36062
27. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys. 2005;2: 413-420 (Pubitemid 39592795)
28. Morris RW, Kaplan NL. On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol. 2002;23: 221-233
29. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;11: 992-998